The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Albrioza sodium phenylbutyrate;ursodoxicoltaurine Orphan | Amylyx Pharmaceuticals EMEA B.V. | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 2023-10-12 | Order → |
| Alendronic Acid / Colecalciferol Mylan alendronate sodium trihydrate;colecalciferol Generic | Mylan S.A.S. | Osteoporosis | 🇪🇺 EU | Order → |
| Aliqopa copanlisib Orphan | Bayer AG | Lymphoma, B-Cell, Marginal Zone | 🇪🇺 EU | Order → |
| Alpheon interferon alfa-2a Biosimilar | BioPartners GmbH | Hepatitis C, Chronic | 🇪🇺 EU 2006-06-28 | Order → |
| Alsitek masitinib Orphan | AB Science | Amyotrophic Lateral Sclerosis | 🇪🇺 EU 2018-04-18 | Order → |
| Ambrisentan Zentiva ambrisentan Generic | Zentiva k.s. | Hypertension, Pulmonary | 🇪🇺 EU | Order → |
| Amlypave anselamimab Orphan | Alexion Europe | Immunoglobulin Light-chain Amyloidosis | 🇪🇺 EU | Order → |
| Amtagvi lifileucel ATMP | Iovance Biotherapeutics B.V. | Melanoma | 🇪🇺 EU | Order → |
| Aplidin plitidepsin Orphan | Pharma Mar S.A. | Multiple Myeloma | 🇪🇺 EU | Order → |
| Apremilast Viatris apremilast | Viatris Limited | Arthritis, Psoriatic; Psoriasis; Behcet Syndrome | 🇪🇺 EU | Order → |
| Aquilda satavaptan | Sanofi-Aventis | Hyponatremia | 🇪🇺 EU | Order → |
| Arikayce amikacin sulfate | Insmed Limited | Mycobacterium Infections | 🇪🇺 EU | Order → |
| Aripiprazole Mylan aripiprazole Generic | Mylan S.A.S. | Schizophrenia | 🇪🇺 EU | Order → |
| Aripiprazole Mylan aripiprazole Generic | Generics (UK) Limited | Schizophrenia; Bipolar Disorder | 🇪🇺 EU | Order → |
| Artobend autologous human chondrocytes in vitro expanded | TETEC Tissue Engineering Technologies AG | Fractures, Cartilage | 🇪🇺 EU | Order → |
| Arxxant ruboxistaurin | Eli Lilly Nederland B.V. | Diabetic Retinopathy | 🇪🇺 EU | Order → |
| Asimtufii aripiprazole | Otsuka Pharmaceutical Netherlands B.V. | Schizophrenia | 🇪🇺 EU | Order → |
| Atropine sulfate FGK atropine | FGK Representative Service GmbH | Myopia | 🇪🇺 EU 2025-09-18 | Order → |
| Aumseqa Aumolertinib | SFL Pharmaceuticals Deutschland GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2026-11-12 | Order → |
| Azacitidine Adienne azacitidine Generic | Adienne S.r.l. S.U. | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myelomonocytic, Acute | 🇪🇺 EU | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.